Memantine for Fragile X-associated Tremor/Ataxia Syndrome (FXTAS): A Randomized, Double-Blind, Placebo-Controlled Trial

OBJECTIVE: Memantine, an NMDA receptor uncompetitive antagonist, is currently approved by the Food and Drug Administration for the treatment of moderate to severe Alzheimer’s disease. Anecdotal reports have suggested that memantine may improve neurological and cognitive symptoms of individuals with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Psychiatry
Main Authors: Seritan, Andreea L., Nguyen, Danh V., Mu, Yi, Tassone, Flora, Bourgeois, James A., Schneider, Andrea, Cogswell, Jennifer, Cook, Kylee, Leehey, Maureen, Grigsby, Jim, Olichney, John M., Adams, Patrick, Legg, Wendi, Zhang, Lin, Hagerman, Paul, Hagerman, Randi J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4296896/
https://ncbi.nlm.nih.gov/pubmed/24345444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4088/JCP.13m08546
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados